全球药物基因组学技术市场研究报告 - 2023 年至 2030 年行业分析、规模、份额、成长、趋势和预测

全球药物基因组学技术市场需求预计将从 2022 年的 76 亿美元增至 2030 年近 155.9 亿美元，2023-2030 年研究期间CAGR为 9.4%。

药物基因组学技术通常缩写为PGx，是一个跨学科领域，它将药物研究（即药理学）和基因及其功能研究（即基因组学）结合起来，以了解个体的基因组成如何影响其对药物的反应。该领域旨在根据个体的基因谱定製药物治疗，最终实现更有效、更安全的药物治疗。

市场动态：

在多种因素的推动下，药物基因组学技术市场正在经历大幅增长，这些因素强调了遗传学在医疗保健中的关键作用以及更有效和个人化治疗的潜力。药物基因组学根据个体的基因谱定製药物治疗，处于医学变革的最前沿。基因组研究的进步以及与药物反应相关的遗传标记的识别正在扩展药物基因组学技术的能力。随着医疗保健提供者和製药公司越来越重视药物的安全性和有效性，药物基因组学透过识别有不良反应风险的患者并优化药物选择和剂量，提供了有价值的解决方案。个人化医疗的兴起，特别是在肿瘤学领域，是一个重要的推动因素，可以根据患者的基因组成製定量身定制的治疗计划。政府措施、精准医疗计划和患者倡导正在进一步促进药物基因组学融入临床实践。伦理考量和负责任的遗传资料被用来强调药物基因组学技术提供更安全、更有效的医疗保健的必要性。製药业在该领域的研发投资以及基因检测技术的日益普及促进了市场的快速扩张。

研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球药物基因组学技术市场的各个细分市场进行了包容性评估。药物基因组学技术产业的成长和趋势为这项研究提供了一种整体方法。

区域分析：

本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲药物基因组技术市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。

该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。药物基因组学技术市场的主要参与者包括 QIAGEN、GE HealthCare、Agilent Technologies, Inc.、F. Hoffmann-La Roche Ltd、FOUNDATION MEDICINE, INC.、Thermo Fisher Scientific Inc.、Leica Biosystems Nussloch GmBH、Pfizer Inc.。包括对竞争格局的整体看法，包括各种策略发展，例如关键併购、未来能力、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。

如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。

目录

第一章：前言

• 报告说明
  • 客观的
  • 目标受众
  • 独特的销售主张 (USP) 和产品
• 研究范围
• 研究方法论
  • 市场研究过程
  • 市场研究方法论

第 2 章：执行摘要

• 市集亮点
• 全球市场概况

第 3 章：药物基因体学技术 - 产业分析

• 简介 - 市场动态
• 市场驱动因素
• 市场限制
• 机会
• 产业动态
• 波特五力分析
• 市场吸引力分析
  • 按治疗领域分類的市场吸引力分析
  • 按技术分類的市场吸引力分析
  • 市场吸引力分析：按地区

第 4 章：价值链分析

• 价值链分析
• 原料分析
  • 原料清单
  • 原料厂商清单
  • 主要原物料价格走势
• 潜在买家名单
• 行销管道
  • 直效行销
  • 间接行销
  • 行销通路发展趋势

第 5 章：全球药物基因组学技术市场分析：按治疗领域

• 按治疗领域概述
• 历史和预测数据
• 按治疗领域分析
• 肿瘤学（肺癌、乳癌、大肠癌、子宫颈癌、其他）
• 神经系统疾病
• 心血管疾病
• 免疫系统疾病
• 传染性疾病
• 其他的

第 6 章：全球药物基因组学技术市场分析：按技术分类

• 依技术概述
• 历史和预测数据
• 依技术分析
• 聚合酶炼式反应
• 原位杂交
• 免疫组织化学
• 定序
• 其他的

第 7 章：全球药物基因组学技术市场分析：按地理位置

• 区域展望
• 介绍
• 北美销售分析
  • 概览、历史与预测资料销售分析
  • 北美按细分市场销售分析
  • 北美按国家销售分析
  • 美国销售分析
  • 加拿大销售分析
  • 墨西哥销售分析
• 欧洲销售分析
  • 概览、历史与预测资料销售分析
  • 欧洲按细分市场销售分析
  • 欧洲按国家销售分析
  • 英国销售分析
  • 法国销售分析
  • 德国销售分析
  • 义大利销售分析
  • 俄罗斯销售分析
  • 欧洲其他地区销售分析
• 亚太地区销售分析
  • 概览、历史与预测资料销售分析
  • 亚太地区按细分市场销售分析
  • 亚太地区国家/地区销售分析
  • 中国销售分析
  • 印度销售分析
  • 日本销售分析
  • 韩国销售分析
  • 澳洲销售分析
  • 东南亚销售分析
  • 亚太地区其他地区销售分析
• 拉丁美洲销售分析
  • 概览、历史与预测资料销售分析
  • 拉丁美洲按细分市场销售分析
  • 拉丁美洲按国家销售分析
  • 巴西销售分析
  • 阿根廷销售分析
  • 秘鲁销售分析
  • 智利销售分析
  • 拉丁美洲其他地区销售分析
• 中东和非洲销售分析
  • 概览、历史与预测资料销售分析
  • 中东和非洲按细分市场销售分析
  • 中东和非洲国家销售分析
  • 沙乌地阿拉伯销售分析
  • 阿联酋销售分析
  • 以色列销售分析
  • 南非销售分析
  • 中东其他地区和非洲销售分析

第 8 章：药物基因体学技术公司的竞争格局

• 药物基因组学技术市场竞争
• 伙伴关係/协作/协议
• 併购
• 新产品发布
• 其他发展

第 9 章：公司简介

• 顶级公司市占率分析
• 市场集中度
• QIAGEN
• 公司简介
• 公司收入
• 产品
• 最近的发展
• GE HealthCare
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Agilent Technologies Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• F. Hoffmann-La Roche Ltd.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• FOUNDATION MEDICINE INC.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Thermo Fisher Scientific Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Leica Biosystems Nussloch GmBH
• 公司简介
• 公司收入
• 产品
• 最近的发展
• Pfizer Inc.
• 公司简介
• 公司收入
• 产品
• 最近的发展

注意 - 在公司概况中，财务详细资讯和近期发展视情况而定，或者如果是私人公司，则可能不包括在内

The global demand for Pharmacogenomics Technology Market is presumed to reach the market size of nearly USD 15.59 BN by 2030 from USD 7.6 BN in 2022 with a CAGR of 9.4% under the study period 2023 - 2030.

Pharmacogenomics technology, often abbreviated as PGx, is an interdisciplinary field that combines the study of drugs, i.e., pharmacology, and the study of genes and their functions, i.e., genomics, to understand how an individual's genetic makeup influences their response to medications. This field aims to tailor drug therapies to an individual's genetic profile, ultimately leading to more effective and safer drug treatments.

MARKET DYNAMICS:

The Pharmacogenomics technology market is experiencing substantial growth driven by a convergence of factors emphasizing the pivotal role of genetics in healthcare and the potential for more effective and personalized treatments. Pharmacogenomics, which tailors drug therapies to an individual's genetic profile, is at the forefront of this transformation in medicine. Advancements in genomic research and the identification of genetic markers associated with drug responses are expanding the capabilities of pharmacogenomics technology. As healthcare providers and pharmaceutical companies increasingly prioritize drug safety and efficacy, pharmacogenomics offers a valuable solution by identifying patients at risk of adverse reactions and optimizing drug selection and dosing. The rise of personalized medicine, particularly in oncology, is a significant driver, enabling tailored treatment plans based on a patient's genetic makeup. Government initiatives, precision medicine programs, and patient advocacy are further promoting the integration of pharmacogenomics into clinical practice. Ethical considerations and responsible genetic data are used to highlight the need for pharmacogenomics technology to provide safer and more effective healthcare. The Pharmaceutical industry's investment in research and development in this field and the increasing accessibility of genetic testing technology contribute to the market's rapid expansion.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of pharmacogenomics technology. The growth and trends of pharmacogenomics technology industry provide a holistic approach to this study.

MARKET SEGMENTATION:

This section of the pharmacogenomics technology market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Therapeutic Area

• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
• Neurological Disorders
• Cardiovascular Disease
• Immunological Disorders
• Infectious Diseases
• Others

By Technology

• PCR
• In-Situ Hybridization
• Immunohistochemistry
• Sequencing
• Others

REGIONAL ANALYSIS:

This section covers the regional outlook, which accentuates current and future demand for the Pharmacogenomics Technology market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Pharmacogenomics Technology market include QIAGEN, GE HealthCare, Agilent Technologies, Inc., F. Hoffmann-La Roche Ltd, FOUNDATION MEDICINE, INC., Thermo Fisher Scientific Inc., Leica Biosystems Nussloch GmBH, Pfizer Inc. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1 . PREFACE

• 1.1. Report Description
  • 1.1.1. Objective
  • 1.1.2. Target Audience
  • 1.1.3. Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1. Market Research Process
  • 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3 . PHARMACOGENOMICS TECHNOLOGY - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Therapeutic Area
  • 3.7.2 Market Attractiveness Analysis By Technology
  • 3.7.3 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1. List of Raw Materials
  • 4.2.2. Raw Material Manufactures List
  • 4.2.3. Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1. Direct Marketing
  • 4.4.2. Indirect Marketing
  • 4.4.3. Marketing Channel Development Trend

5 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY THERAPEUTIC AREA

• 5.1 Overview by Therapeutic Area
• 5.2 Historical and Forecast Data
• 5.3 Analysis by Therapeutic Area
• 5.4 Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Historic and Forecast Sales by Regions
• 5.5 Neurological Disorders Historic and Forecast Sales by Regions
• 5.6 Cardiovascular Disease Historic and Forecast Sales by Regions
• 5.7 Immunological Disorders Historic and Forecast Sales by Regions
• 5.8 Infectious Diseases Historic and Forecast Sales by Regions
• 5.9 Others Historic and Forecast Sales by Regions

6 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY TECHNOLOGY

• 6.1 Overview by Technology
• 6.2 Historical and Forecast Data
• 6.3 Analysis by Technology
• 6.4 PCR Historic and Forecast Sales by Regions
• 6.5 In-Situ Hybridization Historic and Forecast Sales by Regions
• 6.6 Immunohistochemistry Historic and Forecast Sales by Regions
• 6.7 Sequencing Historic and Forecast Sales by Regions
• 6.8 Others Historic and Forecast Sales by Regions

7 . GLOBAL PHARMACOGENOMICS TECHNOLOGY MARKET ANALYSIS BY GEOGRAPHY

• 7.1. Regional Outlook
• 7.2. Introduction
• 7.3. North America Sales Analysis
  • 7.3.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.3.2. North America By Segment Sales Analysis
  • 7.3.3. North America By Country Sales Analysis
  • 7.3.4. United State Sales Analysis
  • 7.3.5. Canada Sales Analysis
  • 7.3.6. Mexico Sales Analysis
• 7.4. Europe Sales Analysis
  • 7.4.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.4.2. Europe by Segment Sales Analysis
  • 7.4.3. Europe by Country Sales Analysis
  • 7.4.4. United Kingdom Sales Analysis
  • 7.4.5. France Sales Analysis
  • 7.4.6. Germany Sales Analysis
  • 7.4.7. Italy Sales Analysis
  • 7.4.8. Russia Sales Analysis
  • 7.4.9. Rest Of Europe Sales Analysis
• 7.5. Asia Pacific Sales Analysis
  • 7.5.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.5.2. Asia Pacific by Segment Sales Analysis
  • 7.5.3. Asia Pacific by Country Sales Analysis
  • 7.5.4. China Sales Analysis
  • 7.5.5. India Sales Analysis
  • 7.5.6. Japan Sales Analysis
  • 7.5.7. South Korea Sales Analysis
  • 7.5.8. Australia Sales Analysis
  • 7.5.9. South East Asia Sales Analysis
  • 7.5.10. Rest Of Asia Pacific Sales Analysis
• 7.6. Latin America Sales Analysis
  • 7.6.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.6.2. Latin America by Segment Sales Analysis
  • 7.6.3. Latin America by Country Sales Analysis
  • 7.6.4. Brazil Sales Analysis
  • 7.6.5. Argentina Sales Analysis
  • 7.6.6. Peru Sales Analysis
  • 7.6.7. Chile Sales Analysis
  • 7.6.8. Rest of Latin America Sales Analysis
• 7.7. Middle East & Africa Sales Analysis
  • 7.7.1. Overview, Historic and Forecast Data Sales Analysis
  • 7.7.2. Middle East & Africa by Segment Sales Analysis
  • 7.7.3. Middle East & Africa by Country Sales Analysis
  • 7.7.4. Saudi Arabia Sales Analysis
  • 7.7.5. UAE Sales Analysis
  • 7.7.6. Israel Sales Analysis
  • 7.7.7. South Africa Sales Analysis
  • 7.7.8. Rest Of Middle East And Africa Sales Analysis

8 . COMPETITIVE LANDSCAPE OF THE PHARMACOGENOMICS TECHNOLOGY COMPANIES

• 8.1. Pharmacogenomics Technology Market Competition
• 8.2. Partnership/Collaboration/Agreement
• 8.3. Merger And Acquisitions
• 8.4. New Product Launch
• 8.5. Other Developments

9 . COMPANY PROFILES OF PHARMACOGENOMICS TECHNOLOGY INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Market Concentration Rate
• 9.3. QIAGEN
  • 9.3.1. Company Overview
  • 9.3.2. Company Revenue
  • 9.3.3. Products
  • 9.3.4. Recent Developments
• 9.4. GE HealthCare
  • 9.4.1. Company Overview
  • 9.4.2. Company Revenue
  • 9.4.3. Products
  • 9.4.4. Recent Developments
• 9.5. Agilent Technologies Inc.
  • 9.5.1. Company Overview
  • 9.5.2. Company Revenue
  • 9.5.3. Products
  • 9.5.4. Recent Developments
• 9.6. F. Hoffmann-La Roche Ltd.
  • 9.6.1. Company Overview
  • 9.6.2. Company Revenue
  • 9.6.3. Products
  • 9.6.4. Recent Developments
• 9.7. FOUNDATION MEDICINE INC.
  • 9.7.1. Company Overview
  • 9.7.2. Company Revenue
  • 9.7.3. Products
  • 9.7.4. Recent Developments
• 9.8. Thermo Fisher Scientific Inc.
  • 9.8.1. Company Overview
  • 9.8.2. Company Revenue
  • 9.8.3. Products
  • 9.8.4. Recent Developments
• 9.9. Leica Biosystems Nussloch GmBH
  • 9.9.1. Company Overview
  • 9.9.2. Company Revenue
  • 9.9.3. Products
  • 9.9.4. Recent Developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company Overview
  • 9.10.2. Company Revenue
  • 9.10.3. Products
  • 9.10.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies

LIST OF TABLES

• Market Snapshot
• Drivers : Impact Analysis
• Restraints : Impact Analysis
• List of Raw Material
• List of Raw Material Manufactures
• List of Potential Buyers
• Analysis by Therapeutic Area (USD MN)
• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Analysis Market by Technology (USD MN)
• PCR Market Sales by Geography (USD MN)
• In-Situ Hybridization Market Sales by Geography (USD MN)
• Immunohistochemistry Market Sales by Geography (USD MN)
• Sequencing Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Pharmacogenomics Technology Market Sales by Geography (USD MN)
• North America Market Analysis (USD MN)
• United State Market Analysis (USD MN)
• Canada Market Analysis (USD MN)
• Mexico Market Analysis (USD MN)
• Europe Market Analysis (USD MN)
• Europe Market Estimate by Country (USD MN)
• United Kingdom Market Analysis (USD MN)
• France Market Analysis (USD MN)
• Germany Market Analysis (USD MN)
• Italy Market Analysis (USD MN)
• Russia Market Analysis (USD MN)
• Spain Market Analysis (USD MN)
• Rest of Europe Market Analysis (USD MN)
• Asia Pacific Market Analysis (USD MN)
• China Market Analysis (USD MN)
• Japan Market Analysis (USD MN)
• India Market Analysis (USD MN)
• South Korea Market Analysis (USD MN)
• Australia Market Analysis (USD MN)
• South East Asia Market Analysis (USD MN)
• Rest of Asia Pacific Market Analysis (USD MN)
• Latin America Market Analysis (USD MN)
• Brazil Market Analysis (USD MN)
• Argentina Market Analysis (USD MN)
• Peru Market Analysis (USD MN)
• Chile Market Analysis (USD MN)
• Rest of Latin America Market Analysis (USD MN)
• Middle East & Africa Market Analysis (USD MN)
• Saudi Arabia Market Analysis (USD MN)
• UAE Market Analysis (USD MN)
• Israel Market Analysis (USD MN)
• South Africa Market Analysis (USD MN)
• Rest of Middle East and Africa Market Analysis (USD MN)
• Partnership/Collaboration/Agreement
• Mergers And Acquisition

LIST OF FIGURES

• Research Scope of Pharmacogenomics Technology Report
• Market Research Process
• Market Research Methodology
• Global Pharmacogenomics Technology Market Size, by Region (USD MN)
• Porters Five Forces Analysis
• Market Attractiveness Analysis by Therapeutic Area
• Market Attractiveness Analysis by Technology
• Market Attractiveness Analysis by Region
• Value Chain Analysis
• Global Market Analysis by Therapeutic Area (USD MN)
• Oncology (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others) Market Sales by Geography (USD MN)
• Neurological Disorders Market Sales by Geography (USD MN)
• Cardiovascular Disease Market Sales by Geography (USD MN)
• Immunological Disorders Market Sales by Geography (USD MN)
• Infectious Diseases Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Analysis by Technology (USD MN)
• PCR Market Sales by Geography (USD MN)
• In-Situ Hybridization Market Sales by Geography (USD MN)
• Immunohistochemistry Market Sales by Geography (USD MN)
• Sequencing Market Sales by Geography (USD MN)
• Others Market Sales by Geography (USD MN)
• Global Market Sales (USD MN)
• North America Market Sales (USD MN)
• Europe Market Sales (USD MN)
• Asia Pacific Market Sales (USD MN)
• Latin America Market Sales (USD MN)
• Middle East & Africa Market Sales (USD MN)
• Recent Development in Industry
• Top Companies Market Share Analysis

Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC.